Biomarkers Market by Offering (Consumables, Software, Services), Type (Safety, Efficacy), Research Area (Genomics, Proteomics), Technology (PCR, MS), Disease (Cancer, Infectious, Neurological), Application (Diagnostic, Research) - Global Forecast to 2030

The biomarkers market is expected to reach USD 104.15 billion in 2030 from USD 62.39 billion in 2025, at a CAGR of 10.8% during the forecast period. The growth of this market can be attributed to the advantage that these assay kits offer standardized and optimized protocols, facilitating accurate and efficient analysis of biomarkers in various biological samples, thus contributing significantly to diagnostic and research endeavors in healthcare. Further, advances in technologies such as genomics, proteomics, metabolomics, and next-generation sequencing have expanded the capabilities of biomarkers. This has led to the development of novel biomarkers with enhanced sensitivity, specificity, and predictive value.

“The predictive biomarkers segment accounted for the largest share of the efficacy biomarkers market in 2024.”

The market by type is segmented into safety, efficacy, and validation biomarkers. Efficacy biomarkers are further segmented into predictive, surrogate, pharmacodynamic, and prognostic biomarkers. In 2024, the predictive biomarkers segment accounted for the largest share of the efficacy biomarkers segment in the global biomarkers market. This large share is supported by the ability of predictive biomarker-based offerings to guide treatment decisions and improve clinical outcomes by identifying patients most likely to benefit from a particular therapeutic intervention, which is especially valuable in oncology, autoimmune disorders, and infectious diseases. Moreover, the growing number of companion diagnostic approvals linked to predictive biomarkers further reinforced their adoption across healthcare settings. For instance, Roche’s PATHWAY anti-HER2/neu (4B5) test identifies HER2-low breast cancer patients eligible for trastuzumab deruxtecan (ENHERTU), which received a label expansion in January 2025 to identify HER2-ultralow patients in HR-positive, HER2-negative metastatic breast cancer.

“Immunoassays held the largest share in the biomarker technologies market in 2024.”

The biomarkers market is segmented by technology into immunoassays, NGS, PCR, mass spectrometry, chromatography, and other technologies. In 2024, immunoassays held the largest market share in the biomarkers market due to their high specificity and ability to detect various biomarkers across various disease areas, particularly in oncology, cardiology, and infectious diseases. Scalability and automation capabilities further support high-throughput testing, meeting the rising demand for precision diagnostics. Major companies are actively advancing immunoassay platforms to enhance their diagnostic offerings. For instance, Roche offers the Elecsys Anti-p53 immunoassay for cancer diagnostics, while Abbott continues to expand its ARCHITECT and Alinity immunoassay systems for infectious disease testing and chronic condition monitoring.

“The Asia Pacific region is growing at the highest CAGR in the biomarkers market during the forecast period.”

The Asia Pacific is projected to register the highest growth rate in the biomarkers market during the forecast period. Key drivers of this growth include a large patient population undergoing advanced medical testing and supportive healthcare policies to improve cancer care. Additionally, increased research activity by pharmaceutical and biotechnology companies to develop novel drug therapies is expected to accelerate market expansion. As investment in drug development continues to rise across the region, the demand for biomarkers that support drug discovery and development efforts is growing steadily.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1- 44%, Tier 2- 32%, and Tier 3- 24%
• By Designation: (Managers)- 45%, (CXOs, Directors)- 30%, and (Executives)- 25%
• By Region: North America- 40%, Europe- 25%, Asia Pacific- 20%, Rest of the World- 15%

F. Hoffmann-La Roche Ltd (Switzerland), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Abbott (US), QIAGEN (Netherlands), Revvity (US), and Laboratory Corporation of America Holdings (US) are some of the key players in the biomarkers market.

The study includes an in-depth competitive analysis of these key players in the biomarkers market, with their company profiles, recent developments, and key market strategies.

Research Coverage:

This research report categorizes the biomarkers market by offering [consumables (assay kits, columns & filters, reagents & chemicals), services, and software], type (safety biomarkers, efficacy biomarkers (surrogate biomarkers, pharmacodynamics biomarkers, predictive biomarkers, and prognostic biomarkers), and validation biomarkers), research area (genomics, proteomics, metabolomics, and other research area), technology [immunoassays (western blot, ELISA, and protein microarray), NGS, PCR, mass spectrometry, chromatography, and other technologies], disease indication (cancer, infectious diseases, cardiovascular disorders, immunological disorders, neurological disorders, and other disease indications), application (clinical diagnostics, drug discovery & development, personalized medicines, clinical research, and other applications), end user (pharmaceutical & biotechnologies companies, hospitals & diagnostics laboratories, research & academic institutes, and other end users), and region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).

The report provides in-depth information on significant factors influencing the growth of the biomarkers market, including drivers, trends, challenges, and opportunities. A thorough analysis of major industry players has been undertaken to provide insights into their business profiles, products/services, key strategies, collaborations, partnerships, and agreements. Additionally, the report encompasses recent developments such as new product launches and acquisitions within the biomarkers market.

Key Benefits of Buying the Report:

The report will help market leaders and new entrants by providing the closest approximations of the revenue numbers for the overall biomarkers market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their businesses and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (increasing use of biomarkers in drug discovery & development, growing importance of companion diagnostics, rising prevalence of cancer, developments of biomarkers for rare diseases, increasing funds and grants for biomarker research, advancement in omics technologies), restraints (high capital investments and extensive timelines for biomarker development, disease complexity, and heterogeneity), opportunities (growing preference for personalized medicine and precision oncology, enhanced collaboration among healthcare providers and key industry players, high growth potential of emerging economies), and challenges (issues associated with quantification and validation of biomarkers, complexities associated with data set integration, technical issues related to sample collection and storage) influencing the growth of the market.
• Product Development/Innovation: Detailed insights on newly launched products/services of the biomarkers market
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products/services, untapped geographies, recent developments, and investments in the biomarkers market
• Competitive Assessment: In-depth assessment of market share, growth strategies and service offerings of leading players like F. Hoffmann-La Roche Ltd (Switzerland), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Abbott (US), QIAGEN (Netherlands), Revvity (US), Laboratory Corporation of America Holdings (US), Charles River Laboratories (US), Bio-Rad Laboratories, Inc. (US), Eurofins Scientific (Luxembourg), BIOMÉRIEUX (France), Agilent Technologies, Inc. (US), JSR Corporation (Japan), and Quanterix (US), among others, in the biomarkers market.

Show more